---
title: 'Risk and incidence of endocrine immune related adverse effects under checkpoint
  inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized
  controlled trials'
date: '2023-11-15'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37967245/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20231116170756&v=2.17.9.post6+86293ac
source: heidelberg[Affiliation]
description: 'CONCLUSION: We showed that risk, independent from cancer type, and incidence
  of eAEs are substantially increased under ICI therapy. Combination of ICIs is increasing
  the risk for eirAEs, in particular for hypophysitis/hypopituitarism. ...'
disable_comments: true
---
CONCLUSION: We showed that risk, independent from cancer type, and incidence of eAEs are substantially increased under ICI therapy. Combination of ICIs is increasing the risk for eirAEs, in particular for hypophysitis/hypopituitarism. ...